What changed for Myasthenia Gravis
A plain English summary of what recently moved in the public data Voxsanity tracks for Myasthenia Gravis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 82 to 83 (+1)
- Trials on record 292 to 289 (-3)
Newly subsidised on the PBS
1 medicine newly subsidised on the PBS for Myasthenia Gravis in July 2026:
- Rozanolixizumab
"Newly subsidised" means the medicine reached the PBS this month, not that a new pack size or brand of an existing listing was added. Verify current PBS status with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 35 trials tracked for Myasthenia Gravis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT03490539 · results posted 18 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 82 people with Myasthenia Gravis (a condition that causes muscle weakness), split into two groups: 34 people received a medicine called Azathioprine (AZT) and 48 people received a medicine called Mycophenolate Mofetil (MMF). All 82 participants who started the trial completed it. The trial was measuring things like quality of life, day-to-day functioning, muscle strength, and the balance between clinical improvement and treatment side effects. The reported data shows that for the two main (primary) outcomes — a quali...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06471361 · results posted 27 March 2026
According to the results reported on ClinicalTrials.gov, this trial involved 31 participants, all of whom completed the study — none dropped out. The trial was examining a medication called zilucoplan, which was delivered using a special auto-injector device (a pen-like device that people use to inject themselves). The main thing being measured was how often the device successfully delivered the full dose of medication when participants injected themselves, across a series of eight clinic visits. The reported data shows that overall, across all visits, 99.8% of self-injection attempts using t...
-
NCT04524273 · results posted 10 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04524273) enrolled 238 people with myasthenia gravis — a condition where the immune system interferes with the signals between nerves and muscles. Participants were divided into groups based on the type of antibody driving their condition (anti-AChR or anti-MuSK), and then randomly assigned to receive either inebilizumab (a study drug given by infusion) or a placebo (an inactive substitute). The trial tracked participants over a main study period and an optional follow-on period. The main goal was to measure changes in two...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04818671 · results posted 22 January 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 180 people, all of whom received a treatment called efgartigimod PH20 SC (given as an injection under the skin). The participants all had myasthenia gravis, a condition that causes muscle weakness. Of the 180 who started, 138 completed the trial and 42 did not finish. The trial was primarily measuring the number of unwanted medical events (called adverse events) that occurred, and secondarily tracking changes in participants' day-to-day functioning, changes in certain proteins in the blood, and how the drug moved thro...
-
NCT05230082 · results posted 18 September 2025
According to the results reported on ClinicalTrials.gov, this trial looked at whether acupuncture had any effect on quality of life and daily activities for people living with myasthenia gravis (MG), a condition that causes muscle weakness. A total of 24 people took part — 10 in a group that started acupuncture straight away ("Immediate Start") and 14 in a group that waited before beginning ("Delayed Start"). By the end of the first 12-week period, 6 of the 10 immediate-start participants and 13 of the 14 delayed-start participants had completed that phase. Both groups then continued into a se...
-
NCT04951622 · results posted 23 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04951622) looked at a medicine called nipocalimab in people with myasthenia gravis — a condition that causes muscle weakness affecting everyday activities like talking, chewing, swallowing, and breathing. The trial had two stages: a 24-week "double-blind" phase (where neither participants nor researchers knew who was getting the real medicine or a dummy treatment called a placebo), followed by an open-label extension phase lasting up to two years where all participants received nipocalimab. In total, 99 people started in t...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05681715 · results posted 7 May 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 62 people in total for an initial six-week training period, after which 55 went on to a self-administration phase. The trial was looking at a medicine called rozanolixizumab (sometimes shortened to RLZ), and its main question was whether people could successfully give themselves this medicine using two different methods: a device called a syringe driver (which automatically pushes the medicine in) and a manual push method (where the person pushes the plunger themselves). The medicine is given as an injection under the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04678115 · results posted 22 April 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 16 people in total — 9 were assigned to try one treatment first and 7 the other way around, with 15 completing the study. It was a crossover trial, meaning each participant tried both treatments at different times, so the same people appear in both treatment groups in the results. The trial was measuring how well two different eyelid-lifting devices helped people open and close their eyes. The two devices tested were a Magnetic Levator Prosthesis (MLP) — a small magnetic device designed to help lift a drooping eyelid...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05514873 · results posted 30 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 26 people who received zilucoplan at a dose of 0.3 mg/kg. The trial was measuring the experiences of participants — particularly any unwanted medical events (called adverse events) that occurred during treatment — as well as changes in two standard rating scales used to assess the day-to-day impact and physical severity of myasthenia gravis, a condition affecting muscle strength. Of the 26 who started the main treatment period, 23 completed it, and those 23 went on to an extension period, of whom 20 completed that sta...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04963270 · results posted 28 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04963270) looked at a medicine called satralizumab in people with a condition called generalised myasthenia gravis (gMG) — a disease that causes muscle weakness affecting things like swallowing, speaking, breathing, and everyday movements. A total of 188 people took part in the main 24-week double-blind phase, with 92 receiving a placebo (an inactive dummy injection) and 96 receiving satralizumab. Neither the participants nor the medical team knew who was getting which treatment during this phase. The main thing being meas...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05218096 · results posted 9 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05218096) enrolled 70 participants with myasthenia gravis (MG) — a condition that causes muscle weakness. Participants were assigned to one of three groups: 28 received a higher dose of the investigational drug ALXN2050 (180 mg twice daily), 14 received a lower dose (120 mg twice daily), and 28 received a placebo (a dummy treatment with no active ingredient). The trial was primarily measuring how many people experienced a meaningful improvement in their ability to carry out everyday activities — scored using a standard que...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03579966 · results posted 7 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03579966) enrolled 63 participants who were all given a medicine called amifampridine phosphate. The trial ran over approximately 39 months and was designed as a long-term safety study — meaning its main goal was to track and count any unwanted or unexpected health events (called adverse events) that occurred while participants were taking the medicine. Only 3 participants completed the full study, while 60 did not complete it; the reasons for not completing were not detailed in the data provided here. The reported data s...
-
NCT05132569 · results posted 8 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05132569) looked at a drug called tolebrutinib in people with myasthenia gravis, a condition that affects muscle strength and daily activities. The trial had two stages: a 26-week double-blind period (where neither participants nor researchers knew who received the real drug or a placebo), followed by an open-label extension (OLE) where all participants received tolebrutinib up to around week 61. In total, only 6 people started the double-blind stage — 3 in the placebo group and 3 in the tolebrutinib group — making this a...
-
NCT03863080 · results posted 20 December 2023
According to the results reported on ClinicalTrials.gov, this was a small clinical trial that enrolled 17 participants in total across two stages. In the first stage — a six-week "double-blind" period (meaning neither participants nor researchers knew who was receiving which treatment) — 17 people were divided into three groups: 6 received a placebo (a dummy treatment), 5 received a lower dose of the investigational medicine RVT-1401 (340 mg per week), and 6 received a higher dose (680 mg per week). After this stage, a 12-week open-label extension followed, where 15 participants received RVT-1...
-
NCT04124965 · results posted 21 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04124965) looked at a medicine called rozanolixizumab in people with myasthenia gravis, a condition that causes muscle weakness. Participants were split into two groups based on the dose they received — roughly 7 mg per kilogram of body weight (35 people) or roughly 10 mg per kilogram (36 people). The trial measured how often participants experienced unwanted health events (called adverse events) during treatment, and also tracked changes in their myasthenia gravis symptoms over time using several standard rating scales....
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03971422 · results posted 21 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03971422) enrolled 200 people with myasthenia gravis — a condition that causes muscle weakness. Participants were split into three groups: 67 received a placebo (an inactive treatment), 66 received a lower dose of rozanolixizumab (approximately 7 mg per kilogram of body weight), and 67 received a higher dose (approximately 10 mg per kilogram). The trial's main goal was to measure how scores on a daily-living disability scale called the MG-ADL changed over roughly six weeks (from the start of the trial to Day 43). This scal...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03770403 · results posted 14 July 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 145 people who received the study treatment, efgartigimod. Of those, 28 completed the trial and 117 did not complete it. The trial was primarily looking at unwanted medical events (called adverse events) that occurred during treatment — including serious ones, those that led to stopping the treatment, and any that resulted in death — in a subgroup of participants who had a specific antibody linked to their condition (known as AChR-positive participants). The reported data shows that, among the AChR-positive subgroup,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04159805 · results posted 2 June 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04159805) enrolled 36 people with myasthenia gravis — a condition that causes muscle weakness — split evenly into three groups of 12: one group received a placebo (a dummy injection with no active ingredient), one received a 300 mg dose of TAK-079, and one received a 600 mg dose of TAK-079. All 12 placebo participants finished the trial, while 10 out of 12 completed in each TAK-079 group. The trial was primarily measuring how often participants experienced unwanted medical events (called adverse events) during the study, a...
-
NCT04735432 · results posted 28 February 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04735432) enrolled 110 people with myasthenia gravis (a condition where the immune system mistakenly attacks the connection between nerves and muscles). Participants were split into two groups of 55: one group received efgartigimod as an injection under the skin (called the SC form, combined with a substance called PH20 to help absorption), and the other received it through a drip into a vein (the IV form). The trial was mainly measuring how much a particular type of antibody in the blood — called total IgG — changed after...
-
NCT04115293 · results posted 17 January 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04115293) enrolled 174 adults with myasthenia gravis (a condition that causes muscle weakness), split into two groups: 88 people received a placebo (an inactive treatment) and 86 received a medicine called zilucoplan at a dose of 0.3 mg/kg. The trial ran for 12 weeks and was primarily measuring changes in a patient-reported score called the MG-ADL — an 8-item questionnaire where a lower score means fewer or less severe symptoms. Several other symptom and quality-of-life scores were also tracked as secondary measures. The...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03759366 · results posted 25 August 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 11 people, all of whom received the study drug eculizumab. The trial was measuring changes in the severity of myasthenia gravis — a condition affecting muscle strength — over 26 weeks. Two scoring tools were used: the QMG (Quantitative Myasthenia Gravis) score, which rates disease severity across 13 areas such as eye movement, swallowing, and breathing on a scale of 0 to 39 (higher meaning more severe), and the MG-ADL (Myasthenia Gravis Activities of Daily Living) score, an 8-question tool rating how the condition aff...
-
NCT03920293 · results posted 26 May 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03920293) enrolled 175 adults with myasthenia gravis — a condition that causes muscle weakness. Eighty-six participants were randomly assigned to receive ravulizumab (an intravenous medicine given by drip), and 89 received a placebo (an inactive dummy treatment) during the first 26-week controlled phase. After that, all participants who continued moved into an open-label extension phase where everyone received ravulizumab. The trial was primarily measuring changes in a standard questionnaire called the MG-ADL, which asks p...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03896295 · results posted 16 February 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03896295) enrolled 37 participants in total — 7 in the "Placebo then Nipocalimab" group and 30 in the "Nipocalimab throughout" group. The trial was measuring the safety and tolerability of nipocalimab, an investigational medicine given by infusion. None of the participants were recorded as having formally "completed" the study under the trial's own definitions, though this does not necessarily mean they did not finish their treatment — it reflects how the trial categorised its milestones. The reported data shows that, loo...
-
NCT03669588 · results posted 8 February 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03669588) enrolled 167 people — 84 received the investigational treatment ARGX-113 and 83 received a placebo (an inactive dummy treatment). The trial was measuring whether people with myasthenia gravis (a condition that causes muscle weakness) showed meaningful improvements in their day-to-day symptoms, using two scoring tools: the MG-ADL scale (an 8-question patient-reported survey about daily activities and symptoms, scored 0–24) and the QMG scale (a 13-item clinician assessment of disease severity, scored 0–39). The mai...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03772587 · results posted 27 October 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03772587) looked at a drug called nipocalimab (also known as M281) in people with myasthenia gravis, a condition that causes muscle weakness. A total of 68 people took part across five groups: one group received a placebo (an inactive treatment), and four groups received different doses or dosing schedules of nipocalimab. The trial measured how many people experienced unwanted medical events (called adverse events), and also tracked changes in participants' day-to-day symptoms using a scoring tool called the MG-ADL, which...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03052751 · results posted 3 August 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03052751) looked at an investigational medicine called UCB7665 in people with myasthenia gravis, a condition that causes muscle weakness. The trial used a crossover design, meaning participants received different treatments at different stages. In the first dosing period, 22 people received a placebo (a dummy treatment with no active ingredient) and 21 received UCB7665 at a dose of 7 mg/kg. Those participants then moved into a second period where they were split into smaller groups receiving different dose combinations. In...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02965573 · results posted 8 January 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02965573) enrolled 24 people in total — 12 received the investigational treatment called ARGX-113 and 12 received a placebo (an inactive dummy treatment). Eleven of the 12 participants in the ARGX-113 group completed the study, while all 12 in the placebo group completed it. The trial was primarily measuring a range of safety-related indicators: unwanted medical events that occurred during treatment (called treatment-emergent adverse events), changes in blood pressure, heart rate, body temperature, and weight, as well as r...
-
NCT02301624 · results posted 5 February 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02301624) enrolled 117 participants in total — 56 in a group that received the medicine eculizumab throughout the study, and 61 in a group that started on a placebo (a dummy treatment) before switching to eculizumab. The trial was looking at a condition called myasthenia gravis, a disease that affects muscle strength. It measured two main things: how many participants experienced unwanted health events (called adverse events) during the study, and how participants' ability to carry out daily activities changed over time, u...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02565576 · results posted 25 July 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02565576) looked at a treatment called CFZ533 compared to a placebo (an inactive treatment) in people with Myasthenia Gravis (MG), a condition that causes muscle weakness. A total of 44 people took part — 22 in the CFZ533 group and 22 in the placebo group. Of these, 17 in each group completed the study, and 5 in each group did not finish. The trial was primarily measuring changes in a standard MG symptom score called the QMG score, which runs from 0 (no symptoms) to 39 (severe symptoms), with a lower score indicating fewer...
-
NCT02970162 · results posted 24 December 2018
According to the results reported on ClinicalTrials.gov, this trial (NCT02970162) enrolled 26 people in total — 13 received amifampridine phosphate and 13 received a placebo (a dummy treatment with no active ingredient). All 26 participants completed the study. The trial was measuring two main things: a doctor-rated score called the Quantitative Myasthenia Gravis (QMG) score, which rates muscle and physical function on a scale from 0 to 39 (where a higher number means more difficulty), and a patient-rated score called the Subject Global Impression (SGI), where participants rated how they felt...
See all 35 reported results for Myasthenia Gravis
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a moderate amount of public research funding is currently directed toward Myasthenia Gravis, and encouragingly, that investment has been rising over time. This upward trend suggests that the scientific community and research funders see value in continuing to explore this condition more deeply. For patients, a growing funding base generally means more research questi...
See the full Myasthenia Gravis page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.